香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Abbisko Cayman Limited 和譽開曼有限責任公司 （於開曼群島註冊成立的有限公司）） （股份代號：2256） 須予披露交易 認購理財產品 認購理財產品 董事會宣佈，於2025年8月28日，本公司與J.P. Morgan Securities plc訂立協議， 據此，本公司同意認購JPMorgan Chase Bank, N.A.發行的美元可贖回零息票 據，認購金額為10.0百萬美元。 認購美元可贖回零息票據前，於2025年7月9日，本公司與J.P. Morgan Securities plc訂立協議，據此，本公司同意認購由J.P. Morgan Structured Products B.V.發 行的與美元兌離岸人民幣匯率掛鈎的美元票據，認購金額為10.0百萬美元。緊 接認購美元可贖回零息票據前，認購與美元兌離岸人民幣匯率掛鈎的美元票據 的尚未償還總結餘約為10.0百萬美元。 上市規則 ...

Group 1 - The company, He Yu-B (02256), announced a share buyback of 100,000 shares at a cost of approximately HKD 1.5937 million on August 28, 2025 [1]

Core Viewpoint - Company He Yu-B (02256) announced a share buyback plan, indicating a strategic move to enhance shareholder value through the repurchase of shares [1] Group 1 - The company plans to repurchase 100,000 shares [1] - The total expenditure for the buyback is approximately HKD 1.5937 million [1] - The buyback is scheduled to occur on August 28, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和譽開曼有限責任公司 呈交日期： 2025年8月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02256 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...

Core Viewpoint - The company is expanding its product portfolio from small molecule innovation in oncology to non-oncology treatments, with significant advancements in drug commercialization and clinical trials [1][2]. Group 1: Product Development - The company has received acceptance for the new drug application (NDA) of Pimicotinib for treating adult tenosynovial giant cell tumors (TGCT) by the National Medical Products Administration (NMPA) in China, with a target date of June 10, 2025 [1]. - Pimicotinib has also been granted breakthrough therapy designation (BTD) by the FDA and priority medicine (PRIME) designation by the EMA, indicating its potential for global commercialization [1]. - The company has initiated the first patient dosing in a registration study for Epaglutide in patients with FGF19 overexpressing hepatocellular carcinoma (HCC), with promising data from ongoing clinical trials [1]. Group 2: Clinical Trials and Collaborations - The company is exploring the combination of ABSK043 (an oral PD-L1 inhibitor) with other therapies for treating KRAS-G12C mutated non-small cell lung cancer (NSCLC) and is conducting a Phase II clinical study for ABSK043 combined with other agents for EGFR mutated NSCLC [2]. - The latest Phase II study results for Epaglutide combined with Atezolizumab showed an overall response rate (ORR) of ≥50% and progression-free survival (PFS) of ≥7 months [1]. Group 3: Financial Projections - Revenue forecasts for the company are projected at 612.1 million, 678.8 million, and 627.2 million yuan for 2025-2027, reflecting year-on-year growth rates of 21.5%, 10.9%, and -7.6% respectively [2]. - The current stock price corresponds to price-to-sales (PS) ratios of 17, 15, and 17 for the years 2025, 2026, and 2027, respectively, indicating potential investment opportunities as the company approaches product commercialization [2].

Summary of Key Points Core Viewpoint - On August 27, 17 Hong Kong-listed companies conducted share buybacks, totaling 7.876 million shares and an amount of 614 million HKD [1]. Group 1: Buyback Details - Tencent Holdings repurchased 909,000 shares for 550 million HKD, with a highest price of 614.50 HKD and a lowest price of 596.00 HKD, accumulating a total buyback amount of 44.448 billion HKD for the year [1][2]. - Hang Seng Bank repurchased 210,000 shares for 23.49 million HKD, with a highest price of 112.20 HKD and a lowest price of 111.50 HKD, totaling 432.12 million HKD in buybacks for the year [1][2]. - MGM China repurchased 1 million shares for 16.018 million HKD, with a highest price of 16.13 HKD and a lowest price of 15.92 HKD, accumulating 134.98 million HKD in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on August 27 was from Tencent Holdings at 550 million HKD, followed by Hang Seng Bank at 23.49 million HKD [1]. - In terms of share quantity, Maple Leaf Education had the highest buyback with 4.492 million shares, followed by MGM China and Tencent Holdings with 1 million and 909,000 shares respectively [1][2]. Group 3: Additional Insights - The buyback by Bruker was its first for the year, while Tencent has conducted multiple buybacks totaling 44.448 billion HKD [2].

Summary of Key Points Core Viewpoint - Multiple companies, including Tencent Holdings and Hang Seng Bank, conducted share buybacks on August 27, 2025, with Tencent leading in both volume and monetary value [1]. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 909,000 shares for a total of 550 million [2]. - Hang Seng Bank (00011) repurchased 210,000 shares amounting to 23.49 million [2]. - MGM China (02282) repurchased 1 million shares for 16.02 million [2]. Group 2: Cumulative Buyback Data - Tencent's cumulative buyback for the year reached 44.82 million shares, representing 0.488% of its total share capital [2]. - Maple Leaf Education (01317) has the highest cumulative buyback at 55.19 million shares, accounting for 1.860% of its total [2]. - Other notable cumulative buybacks include Guichuang Tongqiao-B (02190) at 175,250 shares (0.536%) and Beisen Holdings (09669) at 777,520 shares (1.107%) [2].

和誉-B(02256)发布公告，于2025年8月27日斥资320.12万港元回购20万股股份。 ...

格隆汇8月27日丨和誉-B(02256.HK)公告，8月27日耗资320.1万港元回购20万股。 ...

智通财经APP讯，和誉-B(02256)发布公告，于2025年8月27日斥资320.12万港元回购20万股股份。 ...